P/E ratio for Xencor (XNCR)
P/E ratio as of April 2024 (TTM): -9.34
According to Xencor's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.33645. At the end of 2022 the company had a P/E ratio of -28.3.
P/E ratio history for Xencor from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -28.3 | -200.18% |
| 2021 | 28.3 | -178.36% |
| 2020 | -36.1 | -151.38% |
| 2019 | 70.2 | -360.08% |
| 2018 | -27.0 | 32.96% |
| 2017 | -20.3 | -145.5% |
| 2016 | 44.6 | -243.41% |
| 2015 | -31.1 | 1.42% |
| 2014 | -30.7 | -1870.1% |
| 2013 | 1.73 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -211.13% | 🇺🇸 USA |
 AbbVie ABBV | 43.4 | -564.49% | 🇺🇸 USA |
 Amgen AMGN | 19.1 | -304.36% | 🇺🇸 USA |
 Merck MRK | 72.0 | -871.40% | 🇺🇸 USA |
 Seagen
SGEN | -57.0 | 510.96% | 🇺🇸 USA |
 MacroGenics MGNX | 112 | -1,299.60% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.